Health Care [ 10/12 ] | Biotechnology [ 54/74 ]
NASDAQ | Common Stock
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.
The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.
Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 22, 24 | -0.06 Increased by +25.00% | -0.10 Increased by +40.00% |
| Feb 26, 24 | -0.05 Increased by +61.54% | -0.03 Decreased by -66.67% |
| Nov 8, 23 | -0.12 Increased by +12.73% | -0.05 Decreased by -140.00% |
| Aug 29, 23 | -0.04 Increased by +50.00% | -0.04 |
| May 12, 23 | -0.08 Increased by +65.22% | 0.10 Decreased by -180.00% |
| Mar 29, 23 | -0.13 Decreased by -18.18% | 0.10 Decreased by -230.00% |
| Nov 10, 22 | -0.14 Decreased by -107.31% | -0.14 |
| Aug 11, 22 | -0.08 Decreased by -109.08% | 0.03 Decreased by -366.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 182.12 M Decreased by -7.21% | -94.93 M Decreased by -143.70% | Decreased by -52.13% Decreased by -162.64% |
| Mar 31, 24 | 208.73 M Decreased by -13.28% | -20.67 M Increased by +24.00% | Decreased by -9.90% Increased by +12.36% |
| Dec 31, 23 | 201.31 M Decreased by -16.36% | -16.13 M Increased by +40.70% | Decreased by -8.01% Increased by +29.10% |
| Sep 30, 23 | 196.28 M Increased by +12.88% | -38.95 M Increased by +17.60% | Decreased by -19.85% Increased by +27.00% |
| Jun 30, 23 | 196.28 M Increased by +13.98% | -38.95 M Decreased by -39.44% | Decreased by -19.85% Decreased by -22.34% |
| Mar 31, 23 | 240.69 M Increased by +28.66% | -27.20 M Increased by +13.59% | Decreased by -11.30% Increased by +32.84% |
| Dec 31, 22 | 240.69 M Increased by +28.66% | -27.20 M Increased by +13.59% | Decreased by -11.30% Increased by +32.84% |
| Sep 30, 22 | 173.88 M Increased by +8.91% | -47.27 M Decreased by -135.21% | Decreased by -27.19% Decreased by -132.33% |